ReviewACS omega2025
Ugi and Groebke-Blackburn-Bienaymé Reactions in Medicinal Chemistry: An Outlook on New Bioactive Compounds.
Review in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Synthesis of 5-[3-amino-imidazo[1,2-RSC advances · 2026Article
- Article
- Access to Cyclic Monensin Derivatives via a Four-Component Ugi Reaction.The Journal of organic chemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The FDA has approved 174 new molecular entities over the last 5 years. In 2023, the anticancer and infectious disease areas represented an impressive percentage of drug approvals, 24% and 9%, respectively, following the decade's trends. This reflects the pharmaceutical industry's increasing demand for novel compounds, particularly in these fields. Isocyanide-based multicomponent reactions, such as Ugi and Groebke-Blackburn-Bienaymé reactions, stand out for their versatility in obtaining different bioactive scaffolds using simpler starting materials. A large array of complex scaffold molecules can be obtained by using a multicomponent synthesis step. For this reason, this mini-review summarizes some recent works that employed this approach to afford new anticancer, antiviral, antimicrobial, and antiparasitic compounds. In each case, how the modifications impact activity or cytotoxicity is discussed. Also, the possible gaps that should be evaluated in further work are highlighted to inspire the design of new compounds.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.